Biohit Oyj B
The answer first
Does Biohit beat the market?
No, Biohit has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 69% of Nordic stocks
- Quality95
- Value66
- Trend20
No. 40 of 195 in healthcare
Max for seven days
Follow Biohit with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Biohit
Your first answer is free, no account needed.
Do you own Biohit, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Biohit and a few more. Free, no card.
Super Stock+44.6%In short
- Biohit has fallen 36.0% over the past year, including dividends.
- Overall, Biohit ranks better than 69% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 47.7%. The price is 78.2% below its peak now.
What do analysts think of Biohit?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 69% of Nordic stocks.
No. 40 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 17 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.19
- Asset turnoverSales divided by everything the company owns0.78
- Return on equityProfit divided by equity+19.1%
- Cash conversionOperating cash flow divided by profit−0.23
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 22 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.0
- P/SPrice divided by sales2.1
- P/EPrice divided by earnings10.7
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 127 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−18.8%
- 6 months−9.0%
- 9 months−22.9%
- 12 months−36.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Biohit
Biohit Oyj B is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 47 employees.
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practitioners in interpreting GastroPanel test results; and GP Reader NT for the quantitative determination of various analytes in human samples.


See the full analysis of Biohit.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card